On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


ChineseInvestors.com, Inc.’s (CIIX) CBD Biotechnology Co. Ltd. Developed its CBD Hemp-Infused Rice Wine with ‘Hemp Enthusiasts’ in Mind

  • CIIX’s wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., focuses on benefits of new wine; it has attributed sales gains to hemp oil and alcoholic beverages
  • Life longevity is key issue in its marketing strategy; rice wine is a diet staple in town of Bama, China, which has one of the highest ratios in the world of centenarians-to-general population
  • Warren Wang, CEO of CIIX, noted in a news release that the company had significant growth in its latest fiscal year, largely due to surging hemp oil and alcoholic beverage product sales

ChineseInvestors.com, Inc.’s (OTCQB: CIIX) CBD Biotechnology Co. Ltd., a wholly owned foreign enterprise, plans to market its private brand CBD hemp-infused rice wine in December, focusing on ‘hemp enthusiasts’ and the benefits of the product. Rice wine may be one important factor in the extreme longevity realized in the Chinese town of Bama in Guangxi Province. It is known as the ‘longevity town of China’ and boasts one of the highest ratios of centenarians globally: 73 out of a population of just over 300,000 (http://ibn.fm/dXNsD).

Summer Yun, CEO of CBD Biotech, noted in a recent news release that the company recorded its highest single-day sales of alcoholic beverage products during the 10-day period from September 1-11, 2018. Yun anticipates that the addition of CBD Hemp Wine, scheduled to debut in December 2018, will drive sustained improvement to existing sales performance.

Commenting on company revenue gains in hemp oil and alcoholic beverages, Wang of CIIX said, “Given the trends and the current demands we are seeing in the marketplace, we believe this is a significant opportunity. Moving forward, CBD Biotech plans to explore a variety of hemp products, in addition to its skin-care and alcoholic beverage products.”

The announcement comes after CIIX had reported a 41 percent jump in its sales for FY2018 ended May 31, 2018, as compared to the prior year. CIIX previously detailed plans to spin off its CBD division in the future, including CBD Biotech, Hemp Logic, Inc. and ChineseHempOil.com, Inc. (http://ibn.fm/nwwAc).

CIIX has an international Chinese-speaking audience and generates core revenue from subscriptions and consulting. Its online site, NewCoins168.com, indicates that CIIX expects to issue its own ICO in the second half of 2018 or in 2019 as part of an initiative to create a virtual investment ‘ecosystem’ for its Chinese viewers (http://ibn.fm/3BE7f).

For more information, visit the company’s website at www.ChineseInvestors.com

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.